- Home
- CNTB vs CMRX Comparison
CNTB vs CMRX Comparison
Compare CNTB & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- CMRX
- Stock Information
- Founded
- CNTB 2012
- CMRX 2000
- Country
- CNTB United States
- CMRX United States
- Employees
- CNTB N/A
- CMRX N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- CMRX Health Care
- Exchange
- CNTB Nasdaq
- CMRX Nasdaq
- Market Cap
- CNTB 68.5M
- CMRX 77.0M
- IPO Year
- CNTB 2021
- CMRX 2013
- Fundamental
- Price
- CNTB $1.17
- CMRX $0.93
- Analyst Decision
- CNTB Strong Buy
- CMRX Strong Buy
- Analyst Count
- CNTB 1
- CMRX 1
- Target Price
- CNTB $8.00
- CMRX $11.00
- AVG Volume (30 Days)
- CNTB 24.6K
- CMRX 119.4K
- Earning Date
- CNTB 09-05-2024
- CMRX 11-08-2024
- Dividend Yield
- CNTB N/A
- CMRX N/A
- EPS Growth
- CNTB N/A
- CMRX N/A
- EPS
- CNTB N/A
- CMRX N/A
- Revenue
- CNTB $24,116,000.00
- CMRX $144,000.00
- Revenue This Year
- CNTB N/A
- CMRX $3,040.12
- Revenue Next Year
- CNTB $63.90
- CMRX N/A
- P/E Ratio
- CNTB N/A
- CMRX N/A
- Revenue Growth
- CNTB N/A
- CMRX N/A
- 52 Week Low
- CNTB $0.68
- CMRX $0.75
- 52 Week High
- CNTB $2.84
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- CNTB 44.02
- CMRX 60.78
- Support Level
- CNTB $1.18
- CMRX $0.80
- Resistance Level
- CNTB $1.26
- CMRX $0.98
- Average True Range (ATR)
- CNTB 0.07
- CMRX 0.05
- MACD
- CNTB -0.01
- CMRX 0.01
- Stochastic Oscillator
- CNTB 13.59
- CMRX 83.33
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.